New videos comment on need for follow-on biologics and the creation of an FDA pathway to review and approve those therapies.
Click here to see a video from biotechnology company scientist who calls on Congress to act now. He asks for access to safe, affordable, follow-on biologics, or biogeneric medicines, to treat diseases like MS.
Click here to see a video from Under Secretary of Commerce Dr. Robert J. Shapiro, who identifies potential cost savings of approximately $378 billion over the next 20 years from making follow-on biologics available in the United States.
Tell your story about why Congress needs to act in the interest of patients, savings, and competition. To learn more about what's going on and what you can do, visit www.insmed.com.